Answers are grounded in this paper and cite their sources.
ObjectivesTo assess the frequency and characteristics of late responders (>12 weeks) to monoclonal antibodies (mAbs) targeting the calcitonin gene–related peptide (CGRP). MethodsThis is a multicenter (n = 16) prospective real-life study considering all consecutive adults with high-frequency or chronic migraine treated with anti-CGRP mAbs for ≥24 weeks. We defined responder patients with a ≥50% reduction from baseline in monthly migraine/headache days at weeks 9–12 and late responders as those achieving a ≥50% reduction only afterward. ResultsA total of 771 people with migraine completed ≥24 weeks of anti-CGRP mAb treatment. Responders at 12 weeks were 65.6% (506/771) of the patients, while nonresponders were 34.4% (265/771). A total of 146 of the 265 nonresponders (55.1%) at 12 weeks responded afterward (late responders): they differed from responders for a higher BMI (+0.78, 95% CI [0.10; 1.45]; p = 0.024), more frequent treatment failures (+0.52, 95% CI [0.09; 0.95]; p = 0.017) and psychiatric comorbidities (+10.1%, 95% CI [0.1; 0.20]; p = 0.041), and less common unilateral pain, alone (−10,9%, 95% CI [−20.5; −1.2]; p = 0.025) or in combination with unilateral cranial autonomic symptoms (−12.3%, 95% CI [−20.2;-3.9]; p = 0.006) or allodynia (−10.7, 95% CI [−18.2; −3.2]; p = 0.01). DiscussionHalf of nonresponders to anti-CGRP mAbs at 12 weeks are indeed late responders. Efficacy of anti-CGRP mAbs should be assessed at 24 weeks while treatment duration should be extended beyond 12 months.
No takes yet. Share an insight, caveat, or question.
Barbanti et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: